Hims & Hers Health (NYSE:HIMS) Trading Down 6.7% – Here’s What Happened

Hims & Hers Health, Inc. (NYSE:HIMS)’s stock price fell 6.7% on Friday . The company traded as low as $31.52 and last traded at $30.5440. Approximately 3,703,262 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 27,651,109 shares. The stock had previously closed at $32.74.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: The FDA panel’s favorable peptide recommendation could eventually broaden Hims & Hers’ addressable market and support its emerging peptide therapy business. FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight
• Neutral Sentiment: Truist raised its price target on HIMS to $27 from $23, but kept a hold rating, suggesting the firm sees limited upside from current levels. Tickerreport.com
• Neutral Sentiment: Recent commentary and search interest have kept HIMS in focus, reflecting elevated trading attention around the FDA-driven peptide story. Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
• Negative Sentiment: The sharp pullback appears consistent with a sell-the-news move as traders locked in gains after the initial FDA-related spike, since the regulatory process is not finished. Why Is HIMS Stock Rallying 13% Today?
• Negative Sentiment: Insider selling and mixed hedge fund positioning may also weigh on investor sentiment, as many major holders reduced exposure in the latest quarter. Hims & Hers Health Slides as Traders Fade Peptide Rally

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on HIMS shares. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Truist Financial lifted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Friday. Bank of America boosted their price target on shares of Hims & Hers Health from $36.00 to $37.00 and gave the company a “neutral” rating in a report on Thursday, July 9th. Barclays upped their price objective on shares of Hims & Hers Health from $29.00 to $39.00 and gave the company an “overweight” rating in a research report on Wednesday, June 17th. Finally, Jefferies Financial Group set a $24.50 price objective on Hims & Hers Health in a research note on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $31.43.

Hims & Hers Health Trading Down 14.2%

The firm has a market capitalization of $6.50 billion, a price-to-earnings ratio of -312.26, a price-to-earnings-growth ratio of 79.05 and a beta of 2.35. The business’s fifty day moving average is $30.75 and its 200 day moving average is $26.34. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. During the same period in the previous year, the company posted $0.20 earnings per share. Hims & Hers Health’s revenue for the quarter was up 3.8% on a year-over-year basis. Equities analysts predict that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In related news, insider Patrick Harrison Carroll sold 23,726 shares of the stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $35.00, for a total transaction of $830,410.00. Following the completion of the transaction, the insider directly owned 181,861 shares in the company, valued at approximately $6,365,135. This trade represents a 11.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 7,573 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $30.25, for a total value of $229,083.25. Following the completion of the sale, the insider directly owned 11,280 shares in the company, valued at approximately $341,220. This represents a 40.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 83,126 shares of company stock valued at $2,711,339 over the last ninety days. Company insiders own 11.76% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds have recently made changes to their positions in HIMS. Bank of America Corp DE lifted its position in Hims & Hers Health by 194.4% during the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after purchasing an additional 2,877,550 shares during the period. Norges Bank bought a new position in Hims & Hers Health in the 4th quarter valued at about $62,153,000. Invesco Ltd. increased its holdings in Hims & Hers Health by 62.7% in the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after buying an additional 1,600,004 shares during the period. Marex Group plc raised its position in shares of Hims & Hers Health by 162.2% in the 4th quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock valued at $78,562,000 after buying an additional 1,496,707 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after buying an additional 1,407,651 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.